Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' reply

Maria-Victoria Mateos1, Saad Z Usmani2

  • 1Cancer Research Unit, University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain; Institute of Cancer Molecular and Cellular Biology (USAL-CSIC), Centre for Cancer Research-IBMCC, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.

Abstract

No abstract available in PubMed .

Related Concept Videos